BPC-157 Research: Study Types and Open Questions

BPC-157 turns up in sports forums, wellness clinics and online shops, usually with confident claims about healing. This profile sorts the research by study type (cells, animals, people) and explains what each kind of study can and cannot tell you. We do not give dosing or usage guidance.

What BPC-157 is

BPC-157, also called bepecin or PL 14736, is a synthetic peptide reported to contain 15 amino acids. It was first described in the scientific literature in 1993, and FDA's 2026 review describes it as a fragment of a larger protein called body protection compound, or BPC ^{Source [1]}.

BPC-157 is a common name, not an official drug name. FDA reports that it has found different salts and derivatives sold under the same name, and it treats the free base and the acetate salt as two distinct ingredients ^{Source [1]}. That matters when you read any study or product page: the name alone does not tell you exactly what was tested or sold.

What the animal and cell studies report

Most of the literature is preclinical. In one often-cited experiment, rats with a surgically cut Achilles tendon received the peptide by injection into the abdominal cavity. Compared with saline, treated rats had stronger repaired tendons, better walking function and fuller tissue repair over two weeks, and in cultured tendon cells the peptide countered a chemical that normally slows their growth ^{Source [2]}.

A 2025 systematic review written from a sports medicine perspective found 36 eligible studies. Thirty-five were preclinical, and they reported improved function and structure in muscle, tendon, ligament and bone injury models. The review found no clinical safety data ^{Source [3]}.

FDA's 2026 evaluation adds important caveats. Rat studies also report protection against gut and liver injuries, but dose-response relationships have not been established, the molecular target has not been identified, and how the peptide works remains poorly understood. FDA also judged the available animal toxicity studies too short and too narrow to say anything useful about safety by the routes that had been proposed ^{Source [1]}.

Animal results answer an early question: is there a biological signal worth testing? They cannot show that a product works in people, by which route, or at what amount. Our guide on how to read a peptide study explains why.

What has been studied in people

Human data are sparse. FDA's literature search found five clinical reports ^{Source [1]}:

• A placebo-controlled phase 1 study of a rectal enema in healthy volunteers, published only as meeting abstracts. It looked at tolerability and blood levels, not at any health benefit.
• A placebo-controlled trial in 53 people with mild to moderate ulcerative colitis, also published only as a meeting abstract. Disease scores fell in both groups, and FDA's summary shows no clear difference between them.
• A retrospective chart review of injections into the knee, based on a phone survey of 16 people ^{Source [4]}.
• A single-arm pilot study of injections into the bladder wall in 12 women with interstitial cystitis ^{Source [5]}.
• A pilot safety study of intravenous infusion in two adults who had received the peptide before ^{Source [6]}.

A 2026 systematic review of the human evidence included the last three studies, 30 participants in total. All three reported improvement without treatment-related adverse events, but the reviewers judged them to be of poor methodological quality and rated the overall certainty of evidence as very low ^{Source [7]}. None had a control group, so improvement cannot be separated from natural recovery, other treatment or expectation.

FDA found no human data on how the body absorbs and clears BPC-157 taken by mouth, by injection under the skin, by nasal spray or on the skin. In the enema studies, the peptide was generally not detected in blood ^{Source [1]}.

Two registry records are worth knowing about. A phase 1 trial of an oral tablet in healthy volunteers was registered in 2015; its status is listed as unknown and no results are posted ^{Source [8]}. A randomized, masked phase 1 pilot comparing BPC-157 with a saline sham after rotator cuff repair surgery was registered by the University of Arkansas in 2026 and was not yet recruiting when we checked ^{Source [9]}. A registered trial is a plan, not a result.

Safety: what is known and what is not

FDA searched its adverse event reporting system through December 4, 2025, and found three reports, all involving injected products. Each was complicated by other products used at the same time or by missing detail, so FDA could not tell whether BPC-157 caused the reported events ^{Source [1]}. FDA also raised concern that a 15-amino-acid peptide given by injection or nasal spray may provoke immune reactions, a risk that aggregates and synthesis impurities can amplify ^{Source [1]}.

The absence of reported harm in a few short, small studies is not evidence of long-term safety. FDA concluded that the available information was insufficient to characterize the safety profile.

Regulatory status as of November 3, 2026

BPC-157 is not an FDA-approved drug, and FDA states that no product containing it is approved in any country ^{Source [1]}. FDA's page on compounding substances that may present significant safety risks lists BPC-157 among substances previously in Category 2 whose nominations were withdrawn ^{Source [10]}.

FDA nevertheless evaluated BPC-157 on its own initiative for its July 2026 Pharmacy Compounding Advisory Committee meeting, announced in the Federal Register in April ^{Source [11]}. FDA staff assessed it for ulcerative colitis and proposed not adding it to the 503A bulks list, the list of substances pharmacies may use to compound drugs ^{Source [1]}. On July 23, 2026, according to ABC News, the committee voted 8 to 6, with one abstention, to recommend adding it; the vote is non-binding and still needs FDA sign-off ^{Source [12]}. FDA's meeting page still listed no minutes or official vote results when we checked on November 3, 2026 ^{Source [13]}, but HHS's October policy document states that FDA's drug center recommended against listing and that the committee voted in favor ^{Source [14]}.

On October 30, 2026, HHS published notice of a draft interim policy on 503A compounding with certain peptides ^{Source [15]}. The policy's list names six, BPC-157 among them. Until a final rule decides whether BPC-157 goes on the 503A list, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate in subcutaneous, intramuscular, oral or topical forms, as long as its conditions are met. They include a patient-specific prescription, a single active ingredient, bulk material from an FDA-registered manufacturer with a valid certificate of analysis, and reporting of serious adverse events to FDA ^{Source [14]}. HHS may revisit the policy if a safety signal or product quality problem arises, and the draft is not binding. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold ^{Source [15]}. The policy is enforcement discretion, not an approval and not a listing. We found no proposed rule on BPC-157 in the Federal Register as of November 3, 2026.

In sport, the 2026 WADA Prohibited List names BPC-157 under S0, non-approved substances, which are prohibited at all times ^{Source [16]}.

Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use. The HHS policy concerns pharmacy compounding on a prescription, not products sold as research use only; HHS says it is meant to discourage widespread use of research-use-only peptides from foreign manufacturers, which it describes as a safety risk ^{Source [14]}. For what a lab report can show, see what a certificate of analysis can and cannot tell you.

Open questions

• Does any effect seen in rats occur in people, and for which injuries?
• Which form and route, if any, would deliver the peptide where it would need to act?
• What are the risks of repeated or long-term use, including immune reactions?
• Do products sold as BPC-157 contain the same molecule, salt form and purity as the material that was studied?